Candel Therapeutics is a biotechnology company developing the Gene Mediated Cytotoxic Immunotherapy (GMCI™) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. The Company's lead programs include two randomized studies in prostate cancer, including a Phase 3 under an FDA approved special protocol assessment, as well as ongoing clinical programs in glioma, lung and pancreatic cancer.
Candel Therapeutics total Funding
Candel Therapeutics latest funding size
Time since last funding
|a year ago|
Candel Therapeutics investors
|Sands Capital Ventures, PBM Capital Group, Northpond Ventures, H7 Holdings, Level One Partners|
Who are Candel Therapeutics competitors?
Competitors of Candel Therapeutics include Mendel.ai, Lipella Pharmaceuticals and Immundnz.
Where is Candel Therapeutics headquarters?
Candel Therapeutics headquarters is located at Rosslyn, Arlington.
Where are Candel Therapeutics offices?
Candel Therapeutics has offices in Arlington and Needham.
How many offices does Candel Therapeutics have?
Candel Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies